WHAT IS CLAIMED:

- A method for enhancing fibroblast migration
- 2 at a wound site comprising:
- 3 contacting the wound site with a fibrinogen
- 4 preparation, wherein the fibrinogen preparation includes
- 5 a lipid rich component.
- 1 2. A method according to claim 1 wherein the
- 2 fibrinogen preparation further comprises fibrinogen
- 3 prepared by a process which comprises precipitating
- 4 plasma with glycine.
- 1 3. A method according to claim 2 wherein the
- 2 fibrinogen preparation further comprises a growth factor,
- 3 an extracellular matrix material, or mixtures thereof.
- 1 4. A method according to claim 2 wherein the
- 2 precipitating is carried out by a process which
- 3 comprises:
- 4 adding glycine to plasma to produce a
- 5 precipitate and a supernatant;
- 6 dissolving the precipitate in a buffer to
- 7 produce a solution; and
- 8 precipitating the solution by adding glycine to
- 9 the solution.
- 1 5. A method according to claim 2 wherein the
- 2 fibrinogen in prepared by a process comprising:
- 3 precipitating plasma with glycine to produce a
- 4 first precipitate and a first supernatant;
- 5 dissolving the first precipitate in a buffer to
- 6 produce a first solution;

- 7 precipitating the first solution by adding
- 8 glycine to the first solution to produce a second
- 9 precipitate and a second supernatant;
- 10 dissolving the second precipitate in a buffer
- 11 to produce a second solution; and
- 12 precipitating the second solution by adding
- 13 ammonium sulfate to the second solution to produce a
- 14 third precipitate and a third supernatant.
 - 1 6. A method according to claim 5 wherein the
 - 2 third supernatant comprises a lipid rich layer.
 - 1 7. A method according to claim 6 wherein the
- 2 third supernatant is further treated to produce the lipid
- 3 rich component.
- 1 8. A method according to claim 7 wherein the
- 2 third supernatant is precipitated to produce the lipid
- 3 rich component.
- 1 9. A composition comprising:
- a lipid rich component and
- 3 fibrinogen.
- 1 10. A composition according to claim 9 wherein
- 2 the fibrinogen has a purity of above 95%.
- 1 11. A composition according to claim 9 wherein
- 2 the fibrinogen has a purity of about 99%.
- 1 12. A composition according to claim 9 wherein
- 2 the fibrinogen is prepared by a process which comprises
- 3 precipitating plasma with glycine.

- 1 13. A composition according to claim 12
- 2 wherein the fibrinogen is prepared by a process which
- 3 comprises:
- 4 precipitating plasma with glycine to produce a
- 5 first precipitate and a first supernatant;
- 6 dissolving the first precipitate in a buffer to
- 7 produce a first solution;
- 8 precipitating the first solution by adding
- 9 glycine to the first solution to produce a second
- 10 precipitate and a second supernatant;
- dissolving the second precipitate in a buffer
- 12 to produce a second solution; and
- 13 precipitating the second solution by adding
- 14 ammonium sulfate to the second solution to produce a
- 15 third precipitate and a third supernatant.
 - 1 14. A composition according to claim 9 wherein
 - 2 the lipid rich component is prepared by a process which
 - 3 comprises precipitating plasma with glycine.
 - 1 15. A composition according to claim 14
 - 2 wherein the lipid rich component is prepared by a
 - 3 process which comprises:
 - 4 precipitating plasma with glycine to produce a
- 5 first precipitate and a first supernatant;
- 6 dissolving the first precipitate in a buffer to
- 7 produce a first solution;
- 8 precipitating the first solution by adding
- 9 glycine to the first solution to produce a second
- 10 precipitate and a second supernatant;
- 11 dissolving the second precipitate in a buffer
- 12 to produce a second solution;

precipitating the second solution by adding
ammonium sulfate to the second solution to produce a
third precipitate and a third supernatant; and
precipitating the third supernatant to produce
the lipid rich component.